Superluminal Medicines vs Andson Biotech

Side-by-side comparison of AI visibility scores, market position, and capabilities

Superluminal Medicines leads in AI visibility (86 vs 41)
Superluminal Medicines logo

Superluminal Medicines

LeaderHealthcare

General

Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.

AI VisibilityBeta
Overall Score
A86
Category Rank
#85 of 1158
AI Consensus
59%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
80
Gemini
93

About

Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.

Full profile
Andson Biotech logo

Andson Biotech

EmergingHealthcare

General

Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.

AI VisibilityBeta
Overall Score
C41
Category Rank
#220 of 1158
AI Consensus
62%
Trend
up
Per Platform
ChatGPT
49
Perplexity
36
Gemini
40

About

Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.

Full profile

AI Visibility Head-to-Head

86
Overall Score
41
#85
Category Rank
#220
59
AI Consensus
62
stable
Trend
up
83
ChatGPT
49
80
Perplexity
36
93
Gemini
40
83
Claude
41
95
Grok
51

Key Details

Category
General
General
Tier
Leader
Emerging
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.